P
109.78
-0.01 (-0.01%)
| Previous Close | 109.79 |
| Open | 109.85 |
| Volume | 448,850 |
| Avg. Volume (3M) | 720,500 |
| Market Cap | 7,060,102,144 |
| Price / Earnings (Forward) | 23.26 |
| Price / Sales | 97.07 |
| Price / Book | 10.78 |
| 52 Weeks Range |
| Profit Margin | 27.04% |
| Operating Margin (TTM) | -68.18% |
| Diluted EPS (TTM) | 0.780 |
| Quarterly Revenue Growth (YOY) | -88.90% |
| Quarterly Earnings Growth (YOY) | 381.70% |
| Total Debt/Equity (MRQ) | 1.65% |
| Current Ratio (MRQ) | 17.25 |
| Operating Cash Flow (TTM) | 336.94 M |
| Levered Free Cash Flow (TTM) | 327.76 M |
| Return on Assets (TTM) | 2.48% |
| Return on Equity (TTM) | 8.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Protagonist Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 2.0 |
| Insider Activity | -3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.10% |
| % Held by Institutions | 108.49% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |